FrancophonIA/ELRC3.0 huggingface dataset:
English: Neupopeg was as effective as filgrastim in reducing the duration of severe neutropenia.
Slovenian: Zdravilo Neupopeg je bilo pri skrajšanju trajanja hude nevtropenije enako učinkovito kot filgrastim.
English: Neupopeg is a solution for injection that contains the active ingredient pegfilgrastim.
Slovenian: Zdravilo Neupopeg je raztopina za injiciranje, ki vsebuje zdravilno učinkovino pegfilgrastim.
English: The European Commission granted a marketing authorisation valid throughout the EU for Neupopeg to Dompé Biotec S.p.A. on 22 August 2002.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Neupopeg, veljavno po vsej Evropski uniji, odobrila družbi Amgen Europe B.V.
English: Neupopeg is used to reduce the duration of neutropenia and the occurrence of febrile neutropenia (neutropenia with fever).
Slovenian: Zdravilo Neupopeg se uporablja za skrajšanje trajanja nevtropenije ter zmanjševanje pojavljanja febrilne nevtropenije (nevtropenije s povišano telesno temperature).
English: Why has Neupopeg been approved?
Slovenian: Zakaj je bilo zdravilo Neupopeg odobreno?
English: For the full list of all side effects reported with Neupopeg, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Neupopeg, glejte Navodilo za uporabo.
English: How has Neupopeg been studied?
Slovenian: Kako je bilo zdravilo Neupopeg raziskano?
English: Neupopeg is not recommended for use in children, due to a lack of information on its safety and effectiveness in this group.
Slovenian: Zaradi pomanjkanja podatkov o varnosti in učinkovitosti, zdravilo Neupopeg ni priporočeno za otroke.
English: What is Neupopeg used for?
Slovenian: Za kaj se zdravilo Neupopeg uporablja?
English: The full EPAR for Neupopeg can be found here.
Slovenian: Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Neupopeg je na voljo tukaj.
English: What is Neupopeg?
Slovenian: Kaj je zdravilo Neupopeg?
English: How is Neupopeg used?
Slovenian: Kako se zdravilo Neupopeg uporablja?
English: How does Neupopeg work?
Slovenian: Kako zdravilo Neupopeg deluje?
English: Target Species
Slovenian: Ciljne živalske vrste
English: Pharmaceutical Form
Slovenian: Farmace vtska oblika
English: This summary was last updated: March 2012.
Slovenian: Ta povzetek je bil nazadnje posodobljen: marcu 2012.
English: These side effects occur usually within the first week of treatment and are generally transient (temporary).
Slovenian: Običajno se pojavijo v prvem tednu zdravljenja in so ponavadi prehodni (začasni).
English: It can be used for both acute disorders, such as those seen after an injury, and chronic (long term) disorders.
Slovenian: Lahko se ga uporablja tako za akutna obolenja, do katerih pride ob poškodbi, kot tudi za kronična (dolgotrajna) obolenja.
English: If the product is swallowed by a person, the advice of a doctor should be sought immediately.
Slovenian: V primeru, da človek zdravilo nenamerno zaužije, se je treba nemudoma posvetovati z zdravnikom.
English: Other information about Meloxivet:
Slovenian: Druge informacije o zdravilu Meloxivet:
English: Meloxivet is given to the dog once a day, with food, at the dose of 0.2 mg/kg on the first day, then as 0.1 mg/kg afterwards.
Slovenian: Zdravilo Meloxivet se psu daje enkrat dnevno s hrano v odmerku 0,2 mg/kg na prvi dan, zatem pa v odmerku 0,1 mg/kg.
English: People who are hypersensitive (allergic) to NSAIDs should avoid contact with Meloxivet.
Slovenian: Osebe, ki so preobčutljive za (alergične na) nesteroidna protivnetna zdravila, naj se izogibajo stiku z zdravilom Meloxivet.
English: The amount of suspension to be used is measured using a special dosing syringe (provided in the package), and poured on the food.
Slovenian: Količino suspenzije, ki jo želimo uporabiti, odmerimo s posebno merilno brizgo (priloženo zdravilu) in nato izbrizgamo v hrano.
English: Meloxivet contains meloxicam, which belongs to a class of medicines called nonsteroidal antiinflammatory drugs (NSAIDs).
Slovenian: Zdravilo Meloxivet vsebuje meloksikam, ki spada v skupino zdravil, ki jim pravimo nesteroidna protivnetna zdravila (NSAID).
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Meloxivet on 14 November 2007 Information on the prescription status of this product may be found on the label of the carton.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Meloxivet, veljavno po vsej Evropski uniji, odobrila dne 14. novembra 2007.
English: Meloxivet is used in dogs to relieve inflammation and pain in musculo-skeletal disorders.
Slovenian: Zdravilo Meloxivet se uporablja pri psih za lajšanje vnetja in bolečin pri mišično-kostnih obolenjih.
English: Occasional side effects of Meloxivet are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools and apathy (lack of vitality).
Slovenian: Občasni neželeni učinki zdravila Meloxivet so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in obsegajo izgubo apetita, bruhanje, drisko, kri v blatu in apatijo (pomanjkanje vitalnosti).
English: Therefore the CVMP's view was that, as for Metacam 1.5 mg/ml oral suspension, Meloxivet's benefits are greater than its risks when treating inflammation or pain in muscles or joints in dogs and they recommended that Meloxivet should be given a marketing authorisation.
Slovenian: Zato je CVMP menil, da so koristi zdravila Meloxivet enako kot pri zdravilu Metacam 1,5 mg/ml peroralna suspenzija večje od z njim povezanih tveganj pri zdravljenju vnetja ali bolečine v mišicah ali sklepih pri psih, ter je priporočil odobritev dovoljenja za promet z zdravilom Meloxivet.
English: Why has Meloxivet been approved?
Slovenian: Zakaj je bilo zdravilo Meloxivet odobreno?
English: The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Meloxivet has been shown to be bioequivalent to Metacam 1.5 mg/ml oral suspension.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da se je zdravilo Meloxivet v skladu z zahtevami Evropske unije izkazalo kot bioekvivalentno zdravilu Metacam 1,5 mg/ml peroralna suspenzija.
English: Meloxivet contains the active substance meloxicam and exists in 2 different strengths (0.5 and 1.5 mg/ml, respectively).
Slovenian: Zdravilo Meloxivet vsebuje zdravilno učinkovino meloksikam in je na voljo v 2 različnih jakostih (0,5 in 1,5 mg/ml).
English: Meloxivet is a ‘generic': this means that Meloxivet is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam 1.5 mg/ml oral suspension).
Slovenian: Zdravilo Meloxivet je „generično“ zdravilo, to pomeni, da je podobno „referenčnemu veterinarskemu zdravilu“, ki je že bilo odobreno v EU (zdravilu Metacam 1,5 mg/ml peroralna suspenzija).
English: A study looked at how Meloxivet was absorbed and its effects in the body, in comparison with Metacam 1.5 mg/ml oral suspension.
Slovenian: V študiji so preučevali absorbiranje zdravila Meloxivet ter njegove učinke na telo v primerjavi z zdravilom Metacam 1,5 mg/ml peroralna suspenzija.
English: Meloxivet is a white to yellowish opaque oral suspension which is to be given mixed with food.
Slovenian: Zdravilo Meloxivet je bela do rumenkasta motna peroralna suspenzija, ki se jo daje pomešano med hrano.
English: How has the effectiveness of Meloxivet been studied?
Slovenian: Kako je bila raziskana učinkovitost zdravila Meloxivet?
English: As the prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Slovenian: Prostaglandini sprožajo vnetje, bolečino, izločanje tekočine in zvišano telesno temperaturo, meloksikam pa zmanjša obseg teh odzivov.
English: Studies have been carried out to prove that Meloxivet is ‘bioequivalent' to the reference veterinary medicine: this means that Meloxivet is equivalent to Metacam 1.5 mg/ml suspension in the way it is absorbed and used by the body.
Slovenian: Študije so pokazale, da je zdravilo Meloxivet „bioekvivalentno“ referenčnemu veterinarskemu zdravilu, to pomeni, da je zdravilo Meloxivet enako zdravilu Metacam 1,5 mg/ml peroralna suspenzija glede načina, kako ga telo absorbira in uporabi.
English: What is Meloxivet used for?
Slovenian: Za kaj se zdravilo Meloxivet uporablja?
English: How does Meloxivet work?
Slovenian: Kako zdravilo Meloxivet deluje?
English: What are the side-effects of Meloxivet?
Slovenian: Kakšni so neželeni učinki zdravila Meloxivet?
English: What is Meloxivet?
Slovenian: Kaj je zdravilo Meloxivet?
English: Invented name Strength Pharmaceutical Form Route of administration
Slovenian: Farmacevtska oblika Pot uporabe
English: EU/1/16/1102/001 Bortezomib SUN 3.5 mg Powder for solution for injection Intravenous use, Subcutaneous use vial (glass)
Slovenian: Bortezomib SUN 3,5 mg Prašek za raztopino za injiciranje
English: EU/1/07/424/001 Torisel
Slovenian: EU/1/07/424/001
English: Intravenous use vial (glass) concentrate: 1.2 ml; solvent: 1.8 ml
Slovenian: koncentrat: 1,2 ml; vehikel: 1,8 ml
English: 30 mg Concentrate and solvent for solution for infusion
Slovenian: 30 mg koncentrat in vehikel za raztopino za infundiranje intravenska uporaba viala (steklo)
English: Pack size
Slovenian: Torisel
English: 4 March 2019
Slovenian: 4. marec 2019
English: 3 January 2019
Slovenian: 3. januar 2019
English: The applicant will submit a draft study protocol within 3 months after approval, in Q2 2013 in order to be ready at the time of product launch in 2014.
Slovenian: Vlagatelj bo predložil osnutek protokola študije v treh mesecih po odobritvi, tj. v drugem četrtletju leta 2013, da bi tako bil pripravljen pred dajanjem zdravila na trg leta 2014.
English: The results showed that among the study population compliance is very satisfactory; no firm conclusion could be drawn in special populations.
Slovenian: Rezultati so pokazali, da je upoštevanje navodil za jemanje zdravil v populaciji, ki je sodelovala v študiji, zelo zadovoljivo, medtem ko pri posebnih skupinah bolnikov ni bilo mogoče priti do trdnih zaključkov.
English: November 2018 CMDh meeting
Slovenian: Zasedanje skupine CMDh novembra 2018
English: The Applicant commits to perform a post authorisation safety study (PASS) to assess drug utilisation in real life setting in a representative sample of the European target population.
Slovenian: Predlagatelj se zavezuje, da bo izvedel študijo o varnosti zdravila po pridobitvi dovoljenja za promet (PASS) za oceno uporabe zdravila v stvarnem življenjskem okolju na reprezentativnem vzorcu evropske ciljne populacije.
English: The final study report has been endorsed by the PRAC, and the related condition of the marketing authorisation has been fulfilled.
Slovenian: Odbor PRAC je odobril končno poročilo študije, s tem je bil izpolnjen zadevni pogoj dovoljenja za promet.
English: As part of the initial MA procedure (FR/H/511/01/DC), the MAH Ipsen Pharma committed to conduct a DUS to assess drug utilisation in the real life setting in a representative sample of the European target population.
Slovenian: Kot del prvotnega postopka za pridobitev dovoljenja za promet z zdravilom (FR/H/511/01/DC), se je imetnik dovoljenja za promet Ipsen Pharma zavezal, da bo izvedel študijo o uporabi zdravila (DUS) za oceno uporabe zdravil v stvarnem življenjskem okolju na reprezentativnem vzorcu evropske ciljne populacije.
English: Therefore, in view of available data regarding the PASS final study report, the PRAC considered that changes to the conditions of the marketing authorisation were warranted.
Slovenian: Zato je odbor PRAC ob upoštevanju vseh razpoložljivih podatkov v povezavi s končnim poročilom študije PASS menil, da so potrebne spremembe pogojev dovoljenja za promet.
English: On the basis of the scientific conclusions for the results of the study for the medicinal product(s) containing the active substance magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate and concerned by the PASS final report , the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) mentioned above is unchanged subject to the proposed changes to the product information.
Slovenian: Na podlagi znanstvenih zaključkov o rezultatih študije za zdravilo (zdravila), ki vsebujejo učinkovine magnezijev sulfat heptahidrat, brezvodni natrijev sulfat in kalijev sulfat, ter ob izraženi zaskrbljenosti zaradi končnega poročila študije PASS skupina CMDh meni, da je razmerje med koristmi in tveganji zgoraj navedenih zdravil nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
English: Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Slovenian: Znanstveni zaključki in podlaga za spremembo pogojev dovoljenja (dovoljenj) za promet z zdravilom
English: Taking into account the PRAC Assessment Report for the non-interventional imposed PASS final report for the medicinal product(s) containing the active substance magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate and concerned by the PASS final report , the scientific conclusions are as follows:
Slovenian: Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni končnega poročila odrejene neintervencijske študije o varnosti zdravila po pridobitvi dovoljenja za promet (PASS) za zdravila, ki vsebujejo učinkovine magnezijev sulfat heptahidrat, brezvodni natrijev sulfat in kalijev sulfat, in jih zadeva končno poročilo te študije, so bili sprejeti naslednji znanstveni zaključki:
English: Annex II Conditions of Marketing Authorisation
Slovenian: Pogoji dovoljenja (dovoljenj) za promet z zdravilom
English: Changes to be made to the conditions of the marketing authorisation(s) of medicinal product(s) containing the active substance magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate concerned by the non-interventional imposed PASS final report
Slovenian: Spremembe pogojev dovoljenja (dovoljenj) za promet z zdravili, ki vsebujejo učinkovine magnezijev sulfat heptahidrat, brezvodni natrijev sulfat in kalijev sulfat, in jih zadeva končno poročilo odrejene neintervencijske študije PASS Imetnik (imetniki) dovoljenja za promet z zdravilom mora (morajo) izbrisati naslednji pogoj (naslednje pogoje) (novo besedilo je podčrtano in označeno krepko, izbrisano besedilo prečrtano):
English: • if you have any type of cancer.
Slovenian: • če imate katerokoli vrsto raka.
English: Prevention or treatment of graft-versus-host disease (GVHD).
Slovenian: Preprečevanje ali zdravljenje reakcije presadka proti prejemniku (angl. graft-versus-host disease, GVHD).
English: In a small percentage of patients these changes are more marked and may be of clinical significance.
Slovenian: Pri majhnem odstotku bolnikov so te spremembe bolj izrazite in so lahko klinično pomembne.
English: Paediatric population Interaction studies have only been performed in adults.
Slovenian: Pediatrična populacija Interakcijske študije so izvajali samo pri odraslih.
English: This will get rid of any large air bubbles.
Slovenian: S tem boste odstranili večje mehurčke zraka.
English: For severe rash, the treatment usually lasts for 8 weeks.
Slovenian: Za zdravljenje hude oblike izpuščaja traja zdravljenje običajno 8 tednov.
English: • if you have epilepsy.
Slovenian: • če imate epilepsijo,
English: PHARMACEUTICAL FORM AND CONTENTS Capsule, soft [To be completed nationally]
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA kapsula, mehka [izpolni država članica]
English: Increases in temperatures up to 30°C for a total maximum of 3 months do not affect the quality of the product.
Slovenian: Shranjevanje pri višji temperaturi do 30 °C največ 3 mesece ne vpliva na kakovost zdravila.
English: However, other drinks, such as soft drinks, can be used accordingly to individual taste.
Slovenian: Mogoče je uporabiti tudi druge brezalkoholne pijače po okusu posameznika.
English: Stir and drink the whole contents of the glass straight away.
Slovenian: Premešajte in takoj spijte celotno vsebino kozarca.
English: • if you need to have a vaccination.
Slovenian: • če morate prejeti cepivo.
English: Two, 4 and 8 weeks after the switch, renal function and blood pressure should be monitored.
Slovenian: 2, 4 in 8 tednov po prehodu je treba preveriti ledvično funkcijo in krvni tlak.
English: Precautions to be taken before handling or administering the medicinal product For instructions on dilution of the medicinal product before administration, see section 6.6.
Slovenian: Previdnostni ukrepi potrebni pred ravnanjem z zdravilom ali dajanjem zdravila Za navodila glede redčenja zdravila pred dajanjem, glejte poglavje 6.6.
English: In addition the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000) very rare (<1/10,000), not known (cannot be estimated from the available data).
Slovenian: Ustrezna kategorija pogostnosti pri posameznem neželenem učinku temelji na naslednjem dogovoru (CIOMS III): zelo pogosti (≥ 1/10); pogosti (≥ 1/100, < 1/10); občasni (≥ 1/1.000, < 1/100); redki (≥ 1/10.000, < 1/1.000); zelo redki (< 1/10.000); pogostnost neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: If the renal function (except for proteinuria) is normal, the recommended daily dose is the following: - adults: 5 mg/kg - children: 6 mg/kg
Slovenian: Če je ledvična funkcija normalna (razen proteinurije), je priporočen naslednji dnevni odmerek: - odrasli: 5 mg/kg - otroci: 6 mg/kg
English: Sandimmun Neoral with food and drink
Slovenian: Sandimmun Neoral skupaj s hrano in pijačo
English: It can also be used to maintain steroid-induced remission, allowing withdrawal of steroids.
Slovenian: Zdravilo je mogoče uporabljati tudi za vzdrževanje s steroidi inducirane remisije, kar omogoča ukinitev zdravljenja s steroidi.
English: The intersubject and intrasubject variability for AUC and Cmax is approximately 10-20%.
Slovenian: Interindividualna in intraindividualna variabilnost AUC in Cmax sta približno 10-20 %.
English: If the syringe is to be cleaned, do not rinse it but wipe the outside with a dry tissue (see section 6.6).
Slovenian: Če je treba brizgo očistiti, je ne smete izpirati, lahko pa jo obrišete s suho krpo z zunanje strani (glejte poglavje 6.6).
English: The terminal half-life ranged from 6.3 hours in healthy volunteers to 20.4 hours in patients with severe liver disease (see sections 4.2 and 4.4).
Slovenian: Segajo od 6,3 ure pri zdravih prostovoljcih do 20,4 ure pri bolnikih s težko boleznijo jeter (glejte poglavji 4.2 in 4.4).
English: Push the medicine out of the syringe into a small glass with some liquid (not grapefruit juice).
Slovenian: Iztisnite zdravilo iz brizge v majhen kozarec z nekaj tekočine (vendar ne v sok grenivke).
English: This is because this medicine contains alcohol (see section below “Sandimmun Neoral contains ethanol”).
Slovenian: To je pomembno zato, ker zdravilo vsebuje alkohol (glejte poglavje v nadaljevanju "Zdravilo Sandimmun Neoral vsebuje etanol").
English: • Swelling at the back of the eye which may be associated with an increase in pressure inside the head and eyesight disturbances.
Slovenian: • otekanje na zadnjem delu očesa, ki je lahko povezano s povečanjem tlaka v glavi in motnjami vida
English: If you take more Sandimmun Neoral than you should If you accidentally take too much of your medicine, tell your doctor immediately or go to your nearest hospital emergency unit.
Slovenian: Če ste vzeli večji odmerek zdravila Sandimmun Neoral, kot bi smeli Če ste pomotoma vzeli preveč zdravila, takoj obvestite zdravnika ali pojdite v najbližjo bolnišnično enoto nujne medicinske pomoči.
English: Psoriasis Treatment of severe psoriasis in patients in whom conventional therapy is inappropriate or ineffective.
Slovenian: Psoriaza Zdravljenje hude psoriaze pri bolnikih, pri katerih je običajno zdravljenje neprimerno ali neučinkovito.
English: Sandimmun Neoral capsules may be stored at room temperature not exceeding 25°C.
Slovenian: Kapsule Sandimmun Neoral je mogoče shranjevati pri sobni temperaturi do 25 °C.
English: Additional precautions in psoriasis
Slovenian: Dodatna opozorila pri psoriazi
English: Make sure that the syringe does not touch the liquid in the glass.
Slovenian: Pazite, da se z brizgo pri tem ne dotaknete tekočine v kozarcu.
English: However, there are no adequate and well-controlled studies in pregnant women and therefore Sandimmun Neoral should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the foetus.
Slovenian: Pri nosečnicah pa niso opravili primernih in ustrezno kontroliranih študij, zato se zdravila Sandimmun Neoral med nosečnostjo ne sme uporabljati, razen v primeru, da pričakovana možna korist za mater presega potencialno tveganje za plod.
English: This explains why, in rare cases, Sandimmun Neoral-associated structural kidney alterations have been observed without increases in serum creatinine.
Slovenian: To pojasnjuje, zakaj so v redkih primerih opažali z zdravilom Sandimmun Neoral povezane strukturne spremembe ledvic brez zvišanja koncentracije kreatinina v serumu.
English: • if you have low levels of magnesium in your body.
Slovenian: • če imate znižano koncentracijo magnezija v telesu.
English: Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking this medicine.
Slovenian: Nosečnost in dojenje Posvetujte se s svojim zdravnikom ali farmacevtom, preden začnete jemati to zdravilo.
English: The excretion is primarily biliary, with only 6% of the oral dose excreted in the urine; only 0.1% is excreted in the urine as unchanged parent compound.
Slovenian: Samo 6 % peroralnega odmerka se izloči z urinom in samo 0,1 % se izloči z urinom v obliki nespremenjene matične učinkovine.
English: {Name of the Member State} {Name of the medicinal product} This leaflet was last revised in {MM/YYYY} {month YYYY}.
Slovenian: Navodilo je bilo nazadnje revidirano {MM/LLLL} [izpolni država članica]
English: The relationship between administered dose and exposure (AUC) of ciclosporin is linear within the therapeutic dose range.
Slovenian: Razmerje med danim odmerkom in izpostavljenostjo (AUC) ciklosporinu je v okviru terapevtskih odmerkov linearno.
English: Once satisfactory response is achieved, the dose should be reduced gradually and, if possible, Sandimmun Neoral should be discontinued.
Slovenian: Ko pride do zadovoljivega odziva, je treba odmerek postopoma znižati in, če je mogoče, zdravilo Sandimmun Neoral povsem ukiniti.
English: If your doctor switches you from one oral formulation of ciclosporin to another After you change from one oral formulation of ciclosporin to another:
Slovenian: Če vam je zdravnik zamenjal eno peroralno formulacijo ciklosporina za drugo Po prehodu z ene peroralne oblike ciklosporina na drugo:
English: • Do not store your capsules in a hot place (maximum temperature 25°C).
Slovenian: Kapsul ne shranjujte na toplem (pri temperaturi nad 25 °C).
English: Subsequent use Commence at point 5.
Slovenian: Ponovna uporaba Začnite pri 5. koraku.
English: • Medicines which may increase or decrease the level of ciclosporin (the active substance of Sandimmun Neoral) in your blood.
Slovenian: • zdravila, ki zvišujejo ali znižujejo koncentracijo ciklosporina (zdravilne učinkovine v zdravilu Sandimmun Neoral) v krvi.
English: The lower part of the plunger ring needs to be in front of the mark on the syringe which shows the amount of medicine.
Slovenian: Spodnji del bata mora biti poravnan z oznako na brizgi, ki kaže količino zdravila.
English: Sandimmun Neoral should be prescribed only by physicians who are experienced in immunosuppressive therapy and can provide adequate follow-up, including regular full physical examination, measurement of blood pressure and control of laboratory safety parameters.
Slovenian: Zdravilo Sandimmun Neoral smejo predpisovati samo zdravniki, ki imajo izkušnje z imunosupresivnim zdravljenjem in lahko zagotovijo ustrezno spremljanje bolnika, kar vključuje redne preglede celega telesa, merjenje krvnega tlaka in laboratorijske preiskave varnostnih parametrov.